having spaced from the aryl ring a substituent of carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl; or a pharmaceutically acceptable salt thereof, wherein the disease or condition afflicts or is suspected of afflicting the nervous, hepatic, or respiratory system.

5. (Amended) The method of claim 1 wherein the compound is of the following Formula I:



I

wherein each W is independently optionally substituted alkylene; optionally substituted alkenylene; optionally substituted alkynylene; optionally substituted heteroalkylene; optionally substituted heteroalkenylene; or optionally substituted heteroalkynynylene and further wherein W comprises an unsaturated straight carbon chain;

each Y is independently a carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl;

each R is independently halogen, cyano, nitro, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted carbocyclic aryl; optionally substituted aralkyl;

m is an integer of from 1 to 6; n is an integer of from 0 to 5; and pharmaceutically acceptable salts thereof, with the exclusion of 4-phenylbutyric acid.

Sub B1 Cont 3

8. (Amended) The method of claim 5, wherein the compound further comprises a phenyl ring in the fourth position of the chain.

Sub B1 Cont 4

23. (Amended) The method of claim 22, wherein the compound is administered to the mammal orally, intramuscularly or intraperitoneally.

24. (Amended) A method for treating a mammal suffering from, susceptible to, or recovering from cystic fibrosis (CF), the method comprising administering to the mammal a therapeutically effective amount of at least one carbocyclic aryl compound comprising an unsaturated carbon chain and having spaced from the aryl ring a substituent of carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl compound; or a pharmaceutically acceptable salt thereof.

25. (Amended) The method of claim 1 or 24, wherein the compound increases or decreases expression of a subject protein by at least about 10% in a standard *in vitro* assay for measuring the subject protein.

A5 Sub B1 Cont

29. (Amended) The method of claim 28, wherein the compound exhibits an IC_{50} of about 100 μm or less in the assay.

A6 Sub B1 Cont

34. (Amended) A method for treating a human subject suffering from, susceptible to, or recovering from a disease or condition associated with surfactant protein C, cystic fibrosis (CF) α1 anti-trypsin disease, Alzheimer's disease, Marfan syndrome, familial hypercholesterolemia, or Tay-Sachs disease, the method comprising administering to the human subject a therapeutically effective amount of compound is of the following Formula I:



I

wherein each W is independently optionally substituted alkylene; optionally substituted alkenylene; optionally substituted alkynylene; optionally substituted heteroalkylene; optionally substituted heteroalkenylene; or optionally substituted heteroalkynynylene and further wherein W comprises an unsaturated straight carbon chain;

each Y is independently a carboxy acid, ester, sulfonic acid, nitro, cyano or haloalkyl;

each R is independently halogen, cyano, nitro, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted carbocyclic aryl; optionally substituted aralkyl;

m is an integer of from 1 to 6; n is an integer of from 0 to 5; and pharmaceutically acceptable salts thereof, with the exclusion of 4-phenylbutyric acid.

Kindly add the following new claims 42 and 43.